19.60

4.26% 0.84

Crescent Biopharma Inc (CBIO)

Overview News Price History Discussions Forecast Stock Split Dividend History

Crescent Biopharma Inc stock is traded at $19.60, with a volume of 49,187. It is up +4.26% in the last 24 hours and up +7.65% over the past month. Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Previous Close:

$18.76

Open:

$18.72

24h Volume:

49,187

Relative Volume:

0.20

Market Cap:

$544.60M

Revenue:

$11.88M

Net Income/Loss:

$-162.08M

P/E Ratio:

-1.57

EPS:

-12.484

Net Cash Flow:

$-156.43M

1W Performance:

+9.15%

1M Performance:

+7.65%

6M Performance:

+47.62%

1Y Performance:

+3,726%

1-Day Range:

$18.11

$19.81

1-Week Range:

$16.43

$19.81

52-Week Range:

$8.72

$27.41

Crescent Biopharma Inc Stock (CBIO) Company Profile

Name

Crescent Biopharma Inc

Sector

Healthcare (1110)

Industry

Biotechnology (621)

Phone

617-430-5595

Address

300 FIFTH AVENUE, WALTHAM, CA

Employee

Twitter

@catalystbio

Next Earnings Date

2026-05-13

Latest SEC Filings

CBIO's Discussions on Twitter

Compare CBIO vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CBIO Crescent Biopharma Inc	19.75	517.30M	11.88M	-162.08M	-156.43M	-12.48
VRTX Vertex Pharmaceuticals Inc	439.20	109.09B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	719.87	74.95B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	808.93	48.64B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	291.50	39.39B	4.29B	577.22M	641.34M	4.2086
ONC Beone Medicines Ltd Adr	317.55	32.38B	5.36B	287.73M	924.18M	2.5229

Crescent Biopharma Inc Stock (CBIO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-28-26	Initiated	Piper Sandler	Overweight
Jan-21-26	Initiated	Guggenheim	Buy
Aug-25-25	Initiated	Jefferies	Buy
Aug-11-25	Initiated	H.C. Wainwright	Buy
Jul-14-25	Initiated	Wedbush	Outperform
Jun-25-25	Initiated	Stifel	Buy
Mar-21-25	Initiated	Cantor Fitzgerald	Overweight
Mar-11-25	Initiated	Noble Capital Markets	Outperform
Jul-26-24	Downgrade	TD Cowen	Buy → Hold
Dec-22-23	Initiated	CapitalOne	Overweight
Nov-12-21	Upgrade	Jefferies	Hold → Buy
Apr-29-21	Resumed	Stephens	Overweight
Feb-10-21	Initiated	Piper Sandler	Overweight
May-21-20	Initiated	Raymond James	Outperform
Nov-14-19	Initiated	ROTH Capital	Buy
Aug-05-19	Downgrade	Jefferies	Buy → Hold
Aug-05-19	Downgrade	Piper Jaffray	Overweight → Neutral
Aug-05-19	Downgrade	SunTrust	Buy → Hold
Apr-12-19	Initiated	Piper Jaffray	Overweight
Jan-04-19	Initiated	Oppenheimer	Outperform
Dec-18-18	Initiated	H.C. Wainwright	Buy
Feb-12-18	Reiterated	B. Riley FBR, Inc.	Buy
Feb-09-18	Reiterated	Chardan Capital Markets	Buy
Dec-08-17	Initiated	B. Riley FBR, Inc.	Buy
Jun-12-17	Initiated	Chardan Capital Markets	Buy
Jun-06-17	Initiated	Ladenburg Thalmann	Buy
Jul-26-16	Initiated	SunTrust	Buy
Jun-30-16	Initiated	Rodman & Renshaw	Buy
Mar-17-15	Reiterated	Stifel	Buy

View All

Crescent Biopharma Inc Stock (CBIO) Latest News

May 08, 2026

CBIO Crescent Bio jumps 4% as Q1 loss beats estimates by 27%, pipeline progress lifts investor confidence.Trading Community - newser.com

May 08, 2026

May 07, 2026

Rainbows and Unicorns: Crescent Biopharma, Inc. (NASDAQ:CBIO) Analysts Just Became A Lot More Optimistic - simplywall.st

May 07, 2026

New Forecasts: Here's What Analysts Think The Future Holds For Crescent Biopharma, Inc. (NASDAQ:CBIO) - Moomoo

May 07, 2026

May 06, 2026

Crescent Biopharma lines up 3 May conference webcasts for investors - Stock Titan

May 06, 2026

May 04, 2026

H.C. Wainwright Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $22 - Moomoo

May 04, 2026

May 03, 2026

The numbers behind Crescent Bio (CBIO) stock nobody talks about (Technical Weakness) 2026-05-03Expert Verified Trades - newser.com

May 03, 2026

MSN Money - MSN

May 03, 2026

May 01, 2026

Crude Oil Down 3%; Chevron Posts Mixed Q1 Results - Benzinga

May 01, 2026

Stifel Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Cuts Target Price to $30 - Moomoo

May 01, 2026

Nasdaq Jumps Over 1%; Exxon Mobil Posts Upbeat Revenue - Benzinga

May 01, 2026

Crescent Biopharma Down Over 16%, On Pace for Largest Percent Decrease Since July 2024 -- Data Talk - Moomoo

May 01, 2026